Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...
A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...
A next-generation Novo Nordisk metabolic disorder drug led to statistically significant weight loss in a pivotal test in participants with obesity and type 2 diabetes, results it says ...
Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...
Novo Nordisk stock tumbled Monday morning after disappointing trial results for its CagriSema weight-loss drug. Shares in ...
Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback